Japanese health supplement giant Kobayashi Pharmaceutical is now investigating 76 additional deaths potentially linked to its cholesterol-lowering 'Benikoji' red yeast rice tablets. The announcement Friday marks a dramatic escalation in a crisis that has rattled consumers and raised questions about corporate transparency. 😰
📈 Death Toll Controversy Grows
The Osaka-based company confirmed 1,656 medical inquiries tied to the supplements, with the 76 new cases being examined for direct links. This comes after Japan's health ministry had earlier recognized five confirmed deaths connected to the product. Families are demanding answers as the numbers climb. 💔
⏳ Delayed Disclosure Sparks Fury
Critics accuse Kobayashi of sitting on internal reports of problems since January, only going public on March 22. 'When companies prioritize reputation over safety, it costs lives,' tweeted one activist. The delay has triggered calls for stricter supplement regulations. 📢
🔍 What Happens Next?
With recalls underway and lawsuits looming, all eyes are on how Japan will overhaul its health product oversight. For now, doctors advise against using any Benikoji supplements until investigations conclude. 🩺
